Adverse Drug Reactions and Methodological Approaches to Their Monitoring
https://doi.org/10.33647/2074-5982-17-3-56-61
Abstract
The article is devoted to undesirable drug reactions, an urgent problem of pharmacology. Up-to-date information on their global prevalence is provided, along with methodological approaches to their monitoring. The main directions for the development of the pharmacovigilance system in Russia are outlined.
About the Authors
T. S. Litvinenko
Rostov State Medical University of the Ministry of Health Сare of Russia
Russian Federation
Russian Federation
Tatyana S. Litvinenko
344022, Russian Federation Rostov-on-Don, Nakhichevanskiy Lane, 29
A. V. Safronenko
Rostov State Medical University of the Ministry of Health Сare of Russia
Russian Federation
Russian Federation
Andrey V. Safronenko, Dr. Sci. (Med.), Assoc. Prof.
344022, Russian Federation Rostov-on-Don, Nakhichevanskiy Lane, 29
E. V. Gantsgorn
Rostov State Medical University of the Ministry of Health Сare of Russia
Russian Federation
Russian Federation
Elena V. Gantsgorn, Cand. Sci. (Med.), Assoc. Prof.
344022, Russian Federation Rostov-on-Don, Nakhichevanskiy Lane, 29
O. M. Kudelina
Rostov State Medical University of the Ministry of Health Сare of Russia
Russian Federation
Russian Federation
Oksana M. Kudelina, Cand. Sci. (Med.)
344022, Russian Federation Rostov-on-Don, Nakhichevanskiy Lane, 29
E. S. Postnikova
Rostov State Medical University of the Ministry of Health Сare of Russia
Russian Federation
Russian Federation
Elena S. Postnikova, Cand. Sci. (Med.)
344022, Russian Federation Rostov-on-Don, Nakhichevanskiy Lane, 29
V. A. Chotiy
Rostov State Medical University of the Ministry of Health Сare of Russia
Russian Federation
Russian Federation
Valeria A. Chotiy
344022, Russian Federation Rostov-on-Don, Nakhichevanskiy Lane, 29
References
1. Glagolev S.V., Gorelov K.V., Chizhova D.A. Razvitie sistemy farmakonadzora v Rossijskoj Federacii [Development of the pharmacovigilance system in the Russian Federation]. Bulletin of Roszdravnadzor. 2019;(2):72–77. (In Russian).
2. Gudilina N.A., Rostova N.B. Nezhelatel’nye pobochnye reakcii lekarstvennyh preparatov kak kriterij bezopasnosti terapii [Adverse drug reactions as a safety criterion for therapy]. Medical almanac. 2017;3(48):186–192. (In Russian).
3. Zhuravleva M.V., Romanov B.K., Gorodeckaya G.I., Muslimova O.V., Krysanova V.S., Demchenkova E.Yu. Aktual’nye voprosy bezopasnosti lekarstvennyh sredstv, vozmozhnosti sovershenstvovaniya sistemy farmakonadzora [Topical issues of drug safety, possibilities of improving of pharmacovigilance]. Bezopasnost’ i risk farmakoterapii [Safety and risk of pharmacotherapy]. 2019;7(3):109–119. (In Russian). DOI: 10.30895/2312-7821-2019-7-3-109-119.
4. Lepahin V.K., Romanov B.K., Toropova I.A. Analiz soobshchenij o nezhelatel’nyh reakciyah na lekarstvennye sredstva [Analysis of reports of adverse drug reactions]. Vedomosti NCESMP [Bulletin of NCESMP]. 2012;1:22–25. (In Russian).
5. Litvinenko T.S., Safronenko A.V., Gantsgorn E.V., Dyatchina L.I., Zamlelaya I.V., Myakota I.M., Bystrovskij V.O. Nezhelatel’nye pobochnye reakcii kak aktual’naya problema fundamental’noj i klinicheskoj farma kologii [Undesirable side reactions as an urgent problem of fundamental and clinical pharmacology]. Biomeditsina [Journal Biomed.]. 2020;16(3):115–119. (In Russian). https://doi.org/10.33647/2074-5982-16-3-115-119.
6. Hoseva E.N., Morozova T.E., Ermakov D.A., Oshorova S.D. Voprosy kontrolya bezopasnosti lekarstvennoj terapii v shirokoj klinicheskoj praktike: pozicii pacientov i medrabotnikov [The issues of monitoring the safety of drug therapy in clinical practice: positions of patients and medical workers]. Vrach-aspirant [The doctor-post-graduate student]. 2013;2.1(57):203–212. (In Russian).
7. Shubnikova E.V., Darmostukova M.A., Bukatina T.M., Kaperko D.A., Vel’ts N.Yu., Kazakov A.S., Snegireva I.I., Zhuravleva E.O., Kutekhova G.V. O zaregistrirovannyh v postmarketingovyj period nezhelatel’nyh reakciyah lekarstvennyh sredstv [The adverse drug reactions registered during the postmarketing period]. Bezopasnost’ i risk farmakoterapii [Safety and risk of pharmacotherapy]. 2019;7(1):15–22. (In Russian). DOI: 10.30895/2312-7821-2019-7-1-15-2.
8. Ahern F., Sahm L.J., Lynch D., McCarthy S. Determining the frequency and preventability of adverse drug reaction-related admissions to an Irish University Hospital: a cross-sectional study. Emerg. Med. J. 2014;31:24–29.
9. Akbari Sari A., Doshmangir L., Torabi F., Rashidian A., Sedaghat M., Ghomi R. The incidence, nature and consequences of adverse events in Iranian hospitals. Arch. Iran Med. 2015;18:811–815.
10. Australian Adverse Drug Reaction Reporting System.
11. Australian Adverse Drug Reactions Bulletin.
12. Bénard-Laribière A., Miremont-Salamé G., Pérault- Pochat M-C., Noize P., Haramburu F. Incidence of hospital admissions due to adverse drug reactions in France: the EMIR study. Fundam. Clin. Pharmacol. 2015;29:106–111.
13. http://www.who.int/medicines/areas/rational_use/ru
14. Leendertse A.J., Visser D., Egberts A.C.G., van den Bemt P.M.L.A. The relationship between study characteristics and the prevalence of medication-related hospitalizations: a literature review and novel analysis. Drug Saf. 2010;33:233–244.
15. Medicines and Healthcare Products Regulatory Agency.
16. MedWatch: The FDA Safety Information and Adverse Event Reporting Program.
17. Pedrós C., Quintana B., Rebolledo M., Porta N., Vallano A., Arnau J.M. Prevalence, risk factors and main features of adverse drug reactions leading to hospital admission. Eur. J. Clin. Pharmacol. 2014;70:361–367.
18. Uppsala Monitoring Centre.
Review
For citations:
Litvinenko T.S., Safronenko A.V., Gantsgorn E.V., Kudelina O.M., Postnikova E.S., Chotiy V.A. Adverse Drug Reactions and Methodological Approaches to Their Monitoring. Journal Biomed. 2021;17(3):56-61. (In Russ.) https://doi.org/10.33647/2074-5982-17-3-56-61
Views:
417
Email this article 
